Metachromatic leukodystrophy (MLD) is a rare inborn error of metabolism leading to severe neurological symptoms and early death. Hematopoietic SCT (HSCT) is considered a treatment option, but results are inconsistent and comparison with natural history is practically missing. We compare a girl with juvenile MLD 10 years after allogeneic HSCT not only with her untreated sister, but also with a large cohort of untreated patients. The girl received HSCT at the age of 5 years when first motor signs appeared. Over 10 years she was stable with respect to her clinical course and gained cognitive abilities. Magnetic resonance imaging (MRI) showed clear regression of white matter changes and magnetic resonance spectroscopy (MRS) demonstrated a reversal of the initial choline increase and N-acetyl-aspartate (NAA) decrease. Only axonal demyelinating neuropathy showed some progression. Her gross motor function and MRI-scores were clearly better compared with her sister and the cohort of untreated patients. Difference to her sister became apparent only 4 years after HSCT. We conclude that HSCT, early in the course of disease, can lead to stabilization of juvenile MLD with a course clearly different from the natural history. HSCT may prevent disease progression, if performed sufficient time before loss of walking, which typically initiates rapid deterioration.
INTRODUCTION
Metachromatic leukodystrophy (MLD) is an autosomal recessive disorder caused by mutations in the gene encoding arylsulfatase A (ASA) and deficiency of this enzyme. The defect results in the accumulation of galactosylceramide-3-0-sulfate (sulfatide), predominantly in the central and peripheral nervous system, causing demyelination. MLD occurs with an estimated incidence of about 1 per 100 000 livebirths. 1, 2 More than 100 mutations causing MLD have been described. 3 Clinically, three major forms of MLD can be distinguished based on the age of onset, (i) late-infantile MLD with clinical symptoms beginning before 30 months of age, (ii) juvenile MLD beginning between 2.5 and 16 years and (iii) adult MLD after 16 years of age. 4 Patients with late-infantile MLD have a highly invariable and stereotypic disease course, leading to a complete loss of motor function not later than at the age of 40 months, while overall disease course is more variable in juvenile MLD. 5 Here, impaired fine motor skills, concentration and behavioral problems are additional early symptoms. 6 Psychotic symptoms may occur early in the adult form. 7 Diagnosis of MLD is based on deficiency of ASA activity in leukocytes and sulfatide excretion in urine. Monitoring should include nerve conduction velocity and magnetic resonance imaging (MRI) of the brain. In the latter, T 2 weighted (T2w) imaging typically shows butterfly-shaped confluent white matter hyperintensities with early involvement of the corpus callosum. As the disease progresses, there is increasing white matter involvement including U-fibers and cerebellar white matter as well as cerebral atrophy. 8 Magnetic resonance spectra of MLD patients typically show low N-acetyl-aspartate (NAA) peaks, whereas choline is elevated, and sometimes also lactate. [9] [10] [11] Currently, there is no standardized treatment for patients with MLD. Hematopoietic SCT (HSCT) is thought to result in at least partial continuous, endogenous enzyme production and may delay or prevent disease progression in patients with juvenile MLD. However, results are inconsistent [12] [13] [14] [15] and some authors even consider HSCT in general to be contraindicated in MLD. 15 But comparison of outcome with a cohort with standardized description of the natural disease is lacking.
Here, we present the case of a 15-year-old female patient with juvenile MLD presymptomatically diagnosed, who underwent HSCT at the age of 5 years, when she developed first motor signs. We compare her clinical situation and MRI findings in a 10-year follow-up post HSCT not only with her non-transplanted sister, but also to a group of non-selected juvenile patients, assessed within a nationwide study of the natural-disease course. 5, 8 METHODS MLD was diagnosed in both sisters on the basis of a decrease in ASA activity in leukocytes and elevated sulfatide excretion in urine collected during 24 h. Mutation analysis showed a compound heterozygousity for c.459 þ 1 G4A and p.Pro426Leu. These mutations are known to cause juvenile MLD with onset between 4 and 8 years of age. 16 Informed consent was given by the parents. The study was approved by the Ethical Committee of the University of Tü bingen. MLD). 17 Cognitive function was tested by standard neuropsychological assessments (Kaufmann-ABC, K-ABC and Wechsler-intelligence scale for  children, WISC) 18,19 and school career. Laboratory results included measurement of ASA activity in leukocytes (E/10 6 ) and urinary sulfatide excretion.
MRI and magnetic resonance spectroscopy (MRS).
A severity score was attributed to each magnetic resonance scan with severity ranging from 0 (no abnormalities) up to 34 according to a scoring system based on location and extent of white matter changes as well as the presence of atrophy. 20 Inter-and intra-rater reliability of the rater (Groeschel et al. 8 ) were reported earlier. Demyelinated white matter and overall brain volume was quantified semi-automatically as previously described. 21 Spectroscopy findings were visually analyzed and compared longitudinally in the same location.
Hematological follow-up. Standard post-transplantation follow-up included blood counts, monitoring of thyroid/growth hormones and analyses of chimerism in peripheral blood samples.
Controls
The G-MFC-MLD and MRI scores were used to describe the disease course of the non-transplanted sister and of patients recruited nationwide within the German research network LEUKONET. The number of subjects with juvenile MLD included in the study of motor decline was 38. 5 For the analysis of MRI score related to disease duration, 29 subjects with juvenile MLD were included. 8 In addition, the semi-automatic volumetric method was used for MRI follow-up of the sister.
RESULTS
The older sister of our patient had shown a normal development until the age of 5 years, when she developed gross motor coordination problems and weakness. MLD was diagnosed at the age of 9 years, when she was still able to walk without assistance. Six months later, she lost the ability to walk, showed a rapid decline of gross and fine motor function and developed severe spasticity ( Figure 1 ). Mental decline was observed after the age of 8 years, while active speech was lost at the age of 11 years. Since the age of 12 years she was blind, but still had some basic communication skills (laughed when talked to). MRI at the age of 7.5 years showed periventricular confluent white matter hyperintensity and abnormal signal in the corpus callosum, MRI score was 15. At the age of 19 years there was global white matter hyperintensity and atrophy, MRI score was 31 ( Figure 2) ; demyelinated white matter was 109 mL with a brain volume of 812 mL.
The index patient, 6 years younger, was diagnosed presymptomatically at the age of 2 years 10 months at the time of her sister's diagnosis. She developed normally until the age of nearly 5 years, when she started to show mild motor coordination problems and weakness in the lower limbs, similar to the symptoms of her sister at the same age (Figure 1 ). Her language and cognitive development were considered normal.
Nerve conduction velocity was slightly reduced indicating demyelinating polyneuropathy (Table 1) . MRI scans showed similar changes to her sister's first scan with a score of 14 ( Figure 2 ). MRS showed low NAA and high choline (Figure 3 ).
SCT at the age of 5 years Allo-SCT from an HLA-matched unrelated female donor (levels of ASA in the donor leukocytes were 2.32 E/10 6 cells) was performed after myeloablative chemotherapy including BU (12.8 mg/kg), CY (200 mg/kg) and thymoglobulin (rabbit; 3 Â 10 mg/kg). Stem cell source was G-CSF-mobilized peripheral blood and the graft contained 10.4 Â 10 6 CD34 þ stem cells/kg and 4.2 Â 10 3 residual CD3 þ T cells/kg after immunomagnetic enrichment for CD34-expressing cells.
G-CSF (5 mg/kg) was given from day þ 4 to þ 12, when leukocyte counts reached 1000/mL. The immediate post-transplantation period was complicated by acute veno-occlusive disease of the liver, which resolved under treatment with heparin and defibrotide. Chimerism was complete donor type from day 13 to day 60. On day þ 50 the child was discharged from hospital with normal, stable blood counts. Autologous T cells were detected on day þ 60 at level of 30-40% in peripheral blood, DLI containing 25 000 CD3 þ cells/kg was performed on day þ 87 when autologous T cells had reached 60-80% in the peripheral blood. By day þ 1800 after five DLI without adverse affects, the last given on day þ 1700 (50 000 CD3 þ cells/kg), our patient was back to a stable 90-95% donor chimerism. FACS analysis showed a complete reconstitution of T and B cells. On day þ 1800, after transplantation, her blood counts were normal (WBC 8.32/nL; Hb 11.7 g/dL; platelets 291/nL). Late-adverse effects of the conditioning regimen were not detectable except for an early tremor and a primary amenorrhea. Levels of thyroid and growth hormones remained in the appropriate range until present.
Follow-up after SCT Neurological assessment 18 months after HSCT showed a mild progression of distal weakness and mild ataxia. One year later (age 7.5yrs), mild progression of the peripheral weakness and positive pyramidal signs were seen (hyperreactive reflexes and cloni). Five years after HSCT (age 10 yrs), pyramidal signs were no longer noted, but the mild peripheral polyneuropathy had led to the need for foot orthotics and orthopedic shoes due to flat valgus feet. Nine years after SCT, the patient was still able to walk longer distances. Valgus foot, especially pronounced on the right, was then corrected operatively, followed by an inactivation of several weeks complicated by pneumonia. After prolonged recovery and a marked growth spurt, she was no longer able to walk without aids, but had to use crutches 10 years after HSCT (see also Table 1 ).
Neurophysiology reflected the clinically observed progression of the peripheral neuropathy.
Neuropsychological testing revealed a stable situation with an overall intelligence quotient around 80 with better simultaneous processing capacities (K-ABC) and better verbal intelligence quotient (WISC), respectively. Figure 2 . MRI scans (axial T 2 weighted (T2w) images) pre and post SCT in comparison with the untreated sister (upper row, middle and right). High periventricular and central white matter signal is more prominent and widespread at the age of 6.3 years in comparison with the pre-HSCT MRI at age 4.8 years, but decreases thereafter (see also Table 1 and e-1 for MRI scores and quantification of abnormal white matter, that is, demyelination load). The non-transplanted sister shows similar periventricular signal changes in the frontal and parietooccipital white matter at 7.7 years, whereas at 19.5 years, MRI is characterized by severe and global white matter signal alteration and atrophy. The patient has been attending a regular secondary school with results clearly sufficient to pass grades. Her strengths were the verbal domains (she learns English and French), with some weaknesses in mathematics, especially in geometry. Her social competence has been very good-she was for example elected as a class representative.
MRI ( Figure 2 , Table 1 ) showed progression 16 months past HSCT with more marked and widespread white matter signal changes. However, one year later and also thereafter, white matter signal changes regressed. The increase of white matter changes after HSCT followed by a decrease could be depicted by scoring the MRI scans, and even more so by quantifying the demyelinated white matter in relation to overall brain volume (taking atrophy into account).
MRS findings 16 months after SCT were similar to those before HSCT. One year later, choline had decreased and was lower than the Cr/PCr (Creatin/Phophocreatin) peak and NAA had increased (Figure 3) . Thus, the spectrum had practically normalized, which was unchanged 10 years after HSCT.
Comparison with controls Sister. Both girls had manifested similar motor signs at the same age (around 5 years) and remained stable thereafter for about 4 years, the older sister then showed a fast deterioration of motor function. Thus, a significant difference in motor function was noted only 4 years after HSCT when our patient, in contrast to her untreated sister, remained stable ( Figure 1 ). While our index patient developed normally with respect to language abilities and cognition showing a normal school career, her untreated sister showed a progressive loss of all language and cognitive abilities. MRI looked similar at the beginning of the disease (Figure 2 ) and so were MRI scores, 15 and 14, respectively. Whereas, 11.5 years later the untreated sister showed severe demyelination and atrophy (MRI score 31) in comparison with the transplanted patient with only mild periventricular white matter changes (MRI score 13), resulting in a clearly higher volume of demyelinated white matter (109 mL vs 24 mL). The ratio of demyelinated white matter per brain volume was also clearly higher at last MRI (0.134 vs 0.027).
Natural-course study. Our index patient showed first motor symptoms at the age of 57 months, close to the median of 64.5 months in the natural-course study. 5 HSCT was performed two months later, and our patient remained stable over 10 years until the age of 15 years, when she showed loss of independent walking, that is, level 2 of the G-MFC-MLD. This was beyond the 90th percentile (13.8 years), of the natural-course cohort (median 7.5 years) ( Figure 4) ; patients with juvenile MLD, who had lost independent walking, showed a rapid motor decline to complete loss of gross motor function with a median of 5 months. By contrast, our transplanted patient showed a stable crutches-aided gait after loss of independent walking over 10 months. When comparing the MRI scores of the transplanted patient with the natural-history data, her MRI scores were stable and clearly different from the increasing mean in the untreated MLD cohort ( Figure 5 ). Ten years after disease onset, her MRI score was 13 and below the 95% confidence interval of the untreated cohort (mean 23, 95% confidence interval 14-33, derived from Groeschel et al. 8 ). Table 2 compares the patient's characteristics with those of her sister and the median of the natural-history cohort.
DISCUSSION
The effectiveness of HSCT in MLD is under debate and only a few patients are evaluated with long-term follow-up to date. Therefore, we report on an encouraging long-term outcome in a case with juvenile MLD. One major concern is the comparator for the index patient. The positive influence of HSCT in a transplanted MLD patient to a non-transplanted sibling has been reported earlier. 22 However, substantial variation of phenotype among patients with the same genotype is well known, and may occur even in affected individuals of the same family. 23, 24 Therefore, comparing the index patient not only with affected family members, but also with a cohort of untransplanted MLD patients with standardized and validated tools is necessary to substantiate individual findings and evaluate treatment effectiveness. This case exemplifies a follow-up strategy, which helps to identify patients, who will benefit from HSCT more reliably.
In our index patient, HSCT was done at the age of 5 years, when she had developed first motor signs in terms of weakness of lower limbs and mild coordination problems. At this time, her MRI was already clearly abnormal, and nerve conduction velocity was decreased. HSCT did not cause any detectable chronic side effects, while fertility cannot be judged yet. Following HSCT, the clinical situation initially showed some progression concerning weakness and motor dyscoordination, the gross motor function score, however, remained stable over a follow-up of 9 years post transplant. At this age, the girl lost the ability of unaided walking, which we ascribe to progressive polyneuropathy. In addition, a flat foot operation followed by pneumonia had lead to prolonged inactivation. Cognitive function remained stable with some problems in processing speed and perceptual reasoning, but good verbal competences. Her school performance at the age of 15 years was considered normal, she followed the curriculum of a secondary school.
This clinical course was clearly different in comparison with her untreated sister. However, the difference became evident only after 4 years, when the latter showed a rapid decline of motor and cognitive functions.
Comparing loss of gross motor function with a large cohort of patients with juvenile MLD, she performed well above the 90th percentile of the natural course. A major finding of a nationwide study on the natural course of MLD was a uniform and rapid decline of gross motor function (as rapid as in late-infantile MLD) once independent walking had been lost. 5 When first motor signs had developed, probability was 84% to remain stable before loss of independent walking for more than one year and 51% for more than two years. Obviously, our patient was transplanted early enough to allow the treatment to become effective before this rapid decline began.
MRI changes on follow-up as depicted by a standardized score were clearly different in comparison with a nationwide naturalcourse study of juvenile MLD 8 and to her non-transplanted sister. White matter changes had increased 16 months after HSCT, but one year later, and also thereafter, scores were similar to before HSCT. And a regression of abnormal white matter could be quantified by measuring demyelinated white matter in relation to overall brain volume. The imaging findings in our patient were 8 with permission). The transplanted patient is clearly below the 95% confidence interval of the mean of the natural-course data and remained stable in contrast to the increase in the natural-course. By contrast her sister, starting similarly, showed a massive increase of the MRI score. paralleled by MRS, highly abnormal before HSCT and 16 months later with a high choline and a low NAA signal, but changed to near normal 2.5 years post transplant and thereafter. A normalization of the choline signal suggests reintegration of choline-containing compounds into myelin sheaths. 9, 10 And the increase in NAA signal could indicate neuronal and axonal repair, as its reduction is considered to be due to neuronal and axonal loss and found to be correlated with loss of motor function in MLD. 11 These findings are in accordance with the expectation that therapeutic effects of HSCT in MLD take time to manifest. It is postulated that monocytes expressing and secreting ASA migrate into the brain after HSCT, differentiate into microglia and supply enzyme to deficient resident glia and possibly neurons. [12] [13] [14] [15] There are no histological data available on the dynamic of immigration of monocytes derived from transplanted hematopoietic stem cells into the central nervous system, which underlines the importance of detailed radiologic follow up. Thus, MRI and MRS findings as in our patient are best available evidence that it takes HSCT 1-2 years to become effective, which is longer than the 6-12 months suggested by some authors. 13 The report on three siblings with juvenile MLD who received umbilical cord blood transplantation at different times during their disease and were followed up for 5 years 25, 26 is in line with our observations. The oldest did not benefit, as rapid deterioration set in shortly after transplantation, the second was clinically presymptomatic, but had MRI changes, which had improved two years after umbilical cord blood transplantation and were then stable. The third, also presymptomatic but without MRI abnormalities, developed mild MRI changes 6 months after umbilical cord blood transplantation, which then resolved. In an 8-year follow-up of a transplanted presymptomatic patient, a halt of demyelination and progress of myelination as measured with T2 relaxation times, and stable spectroscopy findings were reported. 27 Stable MRI findings, as visually analyzed, were also reported in a juvenile MLD patients who got HSCT at age 16, two years after first symptoms, and was followed up for 13 years. 28, 29 In conclusion, HSCT early in the disease course can lead to a stabilization of juvenile MLD with a course clearly different from the natural history. We consider a crucial aspect in our patient was that HSCT was done early enough before the loss of walking could be anticipated according to the natural-history data, as this stage typically initiates rapid deterioration. 5 In order to be able to recommend HSCT as therapeutic option for specific patients with juvenile MLD, it seems important to identify other valid features and parameters, which characterize the early stage preceding this rapid decline. In addition to gross motor function, it seems important to learn more about the early course of cognitive functions and also about brain pathology as measured by magnetic resonance techniques. MRI is already abnormal when juvenile MLD gets symptomatic, 8 and we do not know yet which magnetic resonance parameters indicate the start of rapid deterioration.
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